- Home
- EGY vs CELC Comparison
EGY vs CELC Comparison
Compare EGY & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EGY
- CELC
- Stock Information
- Founded
- EGY 1985
- CELC 2011
- Country
- EGY United States
- CELC United States
- Employees
- EGY N/A
- CELC N/A
- Industry
- EGY Oil & Gas Production
- CELC Medical Specialities
- Sector
- EGY Energy
- CELC Health Care
- Exchange
- EGY Nasdaq
- CELC Nasdaq
- Market Cap
- EGY 458.2M
- CELC 440.7M
- IPO Year
- EGY N/A
- CELC 2017
- Fundamental
- Price
- EGY $4.35
- CELC $13.15
- Analyst Decision
- EGY Strong Buy
- CELC Strong Buy
- Analyst Count
- EGY 1
- CELC 6
- Target Price
- EGY $8.00
- CELC $30.17
- AVG Volume (30 Days)
- EGY 697.5K
- CELC 184.2K
- Earning Date
- EGY 03-12-2025
- CELC 03-26-2025
- Dividend Yield
- EGY 5.75%
- CELC N/A
- EPS Growth
- EGY 170.05
- CELC N/A
- EPS
- EGY 0.86
- CELC N/A
- Revenue
- EGY $506,421,000.00
- CELC N/A
- Revenue This Year
- EGY $9.04
- CELC N/A
- Revenue Next Year
- EGY N/A
- CELC N/A
- P/E Ratio
- EGY $5.04
- CELC N/A
- Revenue Growth
- EGY 25.82
- CELC N/A
- 52 Week Low
- EGY $3.96
- CELC $10.35
- 52 Week High
- EGY $7.51
- CELC $22.19
- Technical
- Relative Strength Index (RSI)
- EGY 50.15
- CELC 60.85
- Support Level
- EGY $4.28
- CELC $12.55
- Resistance Level
- EGY $4.49
- CELC $13.25
- Average True Range (ATR)
- EGY 0.11
- CELC 0.68
- MACD
- EGY 0.04
- CELC 0.14
- Stochastic Oscillator
- EGY 72.64
- CELC 85.79
About EGY VAALCO Energy Inc.
VAALCO Energy Inc is an independent energy company operating in the United States. It is principally engaged in the acquisition, exploration, development, and production of crude oil and natural gas. The company operates through geographical segments namely Gabon, Egypt, Canada, Equatorial Guinea and Corporate and Other. The company generates maximum revenue from the Gabon segment.
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.